




LEO Pharma pipeline 2024

PROJECT	DESCRIPTION	PARTNERS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	FILING
Delgocitinib LP0133	A topical pan-JAK inhibitor under development for use in patients with chronic hand eczema.						
Timber TMB-001	A topical isotretinoin in a patented delivery system under development for use in patients with moderate to severe subtypes of congenital ichthyosis.	 					
Temtokibart LP0145	An-IL-22 receptor alpha 1 subunit antagonist under development for use in patients with atopic dermatitis.						
LEO158968 LP0189	A monoclonal antibody under development for use in patients with anti-inflammatory skin diseases.						
IL-17 PPI_m LP0128	An IL-17 PPI modulator.						

**Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority.*

